138 related articles for article (PubMed ID: 14613444)
1. Pharmacoeconomics--determination of the cost-effectiveness of Helicobacter pylori eradication.
Curtiss FR
J Manag Care Pharm; 2003; 9(5):451-2, 455-6. PubMed ID: 14613444
[No Abstract] [Full Text] [Related]
2. Do decision-analytic models identify cost-effective treatments? A retrospective look at helicobacter pylori eradication.
Fairman KA; Motheral BR
J Manag Care Pharm; 2003; 9(5):430-40. PubMed ID: 14613441
[TBL] [Abstract][Full Text] [Related]
3. Pharmacoeconomic comparison of Helicobacter pylori eradication regimens.
Sancar M; Izzettin FV; Apikoglu-Rabus S; Besisik F; Tozun N; Dulger G
Pharm World Sci; 2006 Aug; 28(4):207-14. PubMed ID: 17066247
[TBL] [Abstract][Full Text] [Related]
4. Cost effectiveness in Canada of a multidrug prepackaged regimen (Hp-PAC)+ for Helicobacter pylori eradication.
Agro K; Blackhouse G; Goeree R; Willan AR; Huang JQ; Hunt RH; O'Brien BJ
Pharmacoeconomics; 2001; 19(8):831-43. PubMed ID: 11596835
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analysis and effectiveness of pharmacist-managed outpatient clinics in Helicobacter pylori eradication therapy.
Seko T; Tachi T; Hatakeyama H; Noguchi Y; Teramachi H
Int J Clin Pract; 2019 Jun; 73(6):e13349. PubMed ID: 30912226
[TBL] [Abstract][Full Text] [Related]
6. [Pharmacoeconomics in helicobacter pylori infection (lecture)].
Isakov VA; Ivanikov IO
Ter Arkh; 2000; 72(2):61-3. PubMed ID: 10717932
[No Abstract] [Full Text] [Related]
7. Pharmacoeconomics in HP-related diseases: more questions than answers.
Deltenre M; De Bruyne I; Jonas C; De Koster E
Acta Gastroenterol Belg; 1998; 61(3):352-6. PubMed ID: 9795472
[No Abstract] [Full Text] [Related]
8. Economics of Helicobacter pylori eradication therapy.
Deltenre MA
Eur J Gastroenterol Hepatol; 1997 Apr; 9 Suppl 1():S23-6; discussion S27-9. PubMed ID: 9160213
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of Helicobacter pylori eradication in India: to live and let live ... expensively?
Bhatia SJ; Kulkarni SG
Indian J Gastroenterol; 1997 Nov; 16 Suppl 1():S25-8. PubMed ID: 9465500
[No Abstract] [Full Text] [Related]
10. Decision analysis of histamine H2-receptor antagonist maintenance therapy versus Helicobacter pylori eradication therapy: a randomised controlled trial in patients with continuing pain after duodenal ulcer.
Tavakoli M; Prach AT; Malek M; Hopwood D; Senior BW; Murray FE
Pharmacoeconomics; 1999 Oct; 16(4):355-65. PubMed ID: 10623364
[TBL] [Abstract][Full Text] [Related]
11. Immediate eradication of Helicobacter pylori in patients with previously documented peptic ulcer disease: clinical and economic effects.
Fendrick AM; McCort JT; Chernew ME; Hirth RA; Patel C; Bloom BS
Am J Gastroenterol; 1997 Nov; 92(11):2017-24. PubMed ID: 9362183
[TBL] [Abstract][Full Text] [Related]
12. Varying efficacy of Helicobacter pylori eradication regimens: cost effectiveness study using a decision analysis model.
Duggan AE; Tolley K; Hawkey CJ; Logan RF
BMJ; 1998 May; 316(7145):1648-54. PubMed ID: 9603748
[TBL] [Abstract][Full Text] [Related]
13. Eradication therapy for Helicobacter pylori.
Vakil N; Megraud F
Gastroenterology; 2007 Sep; 133(3):985-1001. PubMed ID: 17854602
[TBL] [Abstract][Full Text] [Related]
14. Endoscopy Is Cost-Effective for Gastric Cancer Screening After Successful Helicobacter pylori Eradication.
Kowada A
Dig Dis Sci; 2021 Dec; 66(12):4220-4226. PubMed ID: 33417196
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of Helicobacter pylori eradication for the long-term management of duodenal ulcer in Canada.
O'Brien B; Goeree R; Mohamed AH; Hunt R
Arch Intern Med; 1995 Oct; 155(18):1958-64. PubMed ID: 7575049
[TBL] [Abstract][Full Text] [Related]
16. The cost effectiveness of Helicobacter pylori eradication versus maintenance and episodic treatment in duodenal ulcer patients in Sweden.
Unge P; Jönsson B; Stålhammar NO
Pharmacoeconomics; 1995 Nov; 8(5):410-27. PubMed ID: 10160075
[TBL] [Abstract][Full Text] [Related]
17. Management of Helicobacter pylori in duodenal ulcer: a cost-effectiveness analysis.
García-Altés A; Jovell AJ; Serra-Prat M; Aymerich M
Aliment Pharmacol Ther; 2000 Dec; 14(12):1631-8. PubMed ID: 11121912
[TBL] [Abstract][Full Text] [Related]
18. Helicobacter pylori eradication regimens in an antibiotic high-resistance European area: A cost-effectiveness analysis.
Papaefthymiou A; Liatsos C; Georgopoulos SD; Apostolopoulos P; Doulberis M; Kyriakos N; Giakoumis M; Papadomichelakis M; Galanopoulos M; Katsinelos P; Rokkas T; Kountouras J
Helicobacter; 2020 Feb; 25(1):e12666. PubMed ID: 31692137
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of Helicobacter pylori eradication therapy at a company occupational health clinic in Japan.
Yamasaki T
J UOEH; 2002 Jun; 24(2):161-76. PubMed ID: 12066584
[TBL] [Abstract][Full Text] [Related]
20. Modelling cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer: a mandate for clinical trials.
Parsonnet J; Harris RA; Hack HM; Owens DK
Lancet; 1996 Jul; 348(9021):150-4. PubMed ID: 8684154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
